GenoME Diagnostics Ltd develops OvaME, a blood test that utilizes biomarker discovery techniques for the early and accurate diagnosis of ovarian cancer. This technology addresses the challenges of misdiagnosis and late detection, enabling timely intervention and improved patient outcomes.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Ovarian cancer is often misdiagnosed or detected late, leading to delayed intervention and poorer patient outcomes. Current diagnostic methods lack the sensitivity and specificity needed for early and accurate detection.
Solution
GenoME Diagnostics is developing OvaME, a blood test designed for the earlier and more accurate diagnosis of ovarian cancer. OvaME utilizes biomarker discovery techniques to identify specific indicators in the blood, enabling timely intervention and improved patient outcomes. The test aims to improve the ovarian cancer diagnostic pathway by providing a user-friendly and cost-effective solution. GenoME's technology can also be applied to biomarker discovery and development for a wide range of other diseases.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and women at risk of or suspected of having ovarian cancer.
Features
- Blood-based diagnostic test for ovarian cancer
- Utilizes biomarker discovery techniques for early detection
- Aims to improve the accuracy and speed of diagnosis
- Cost-effective and user-friendly design
- Potential application for biomarker discovery in other diseases